User profiles for Reed F. Beall

Reed F Beall

Assistant Professor, University of Calgary
Verified email at ucalgary.ca
Cited by 906

[HTML][HTML] Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997

B Sahragardjoonegani, RF Beall… - … of pharmaceutical policy …, 2021 - Springer
Background Drug repurposing (ie, finding novel uses for existing drugs) is essential for
maximizing medicines’ therapeutic utility, but obtaining regulatory approval for new indications is …

Evaluating the impact of the Orphan Drug Act's seven-year market exclusivity period

A Sarpatwari, RF Beall, A Abdurrob, M He… - Health …, 2018 - healthaffairs.org
For thirty-five years the Orphan Drug Act of 1983 has provided incentives for pharmaceutical
manufacturers to develop drugs to treat rare diseases—conditions that affect fewer than …

Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986–2020: Study examines patents and regulatory exclusivities on inhalers for asthma and …

WB Feldman, D Bloomfield, RF Beall… - Health Affairs, 2022 - healthaffairs.org
Inhalers are the mainstay of treatment for asthma and chronic obstructive pulmonary disease
(COPD). These products face limited generic competition in the US and remain expensive. …

[HTML][HTML] Is patent “evergreening” restricting access to medicine/device combination products?

RF Beall, JW Nickerson, WA Kaplan, A Attaran - PLoS One, 2016 - journals.plos.org
Background Not all new drug products are truly new. Some are the result of marginal innovation
and incremental patenting of existing products, but in such a way that confers no major …

COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022

B Lau, M Tadrous, C Chu, L Hardcastle, RF Beall - Cmaj, 2022 - Can Med Assoc
Background: In March 2020, the Government of Canada introduced measures to reduce
intensifying shortages of prescription drugs during the beginning of the COVID-19 pandemic. …

The characteristics of patents impacting availability of biosimilars

VL Van de Wiele, RF Beall, AS Kesselheim… - Nature …, 2022 - nature.com
The large number of biologic drug patents in the United States has contributed to delays in
biosimilar availability.

Pre-market development times for biologic versus small-molecule drugs

RF Beall, TJ Hwang, AS Kesselheim - Nature Biotechnology, 2019 - nature.com
3. Regalado, A. More than 26 million people have taken an at-home ancestry test. MIT
Technology Review https://www. technologyreview. com/s/612880/more-than-26-million-…

[HTML][HTML] Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019

A Olsen, RF Beall, RP Knox, SS Tu… - Plos …, 2023 - journals.plos.org
Background Insulin is the primary treatment for type 1 and some type 2 diabetes but remains
costly in the United States, even though it was discovered more than a century ago. High …

Patents and regulatory exclusivities on GLP-1 receptor agonists

R Alhiary, AS Kesselheim, S Gabriele, RF Beall, SS Tu… - JAMA, 2023 - jamanetwork.com
Importance Glucagon-like peptide 1 (GLP-1) receptor agonists were first approved for the
treatment of type 2 diabetes in 2005. Demand for these drugs has increased rapidly in recent …

[HTML][HTML] A method for approximating future entry of generic drugs

RF Beall, JJ Darrow, AS Kesselheim - Value in Health, 2018 - Elsevier
Objectives To develop and test a method for approximating generic entry of top-selling drugs.
Methods The procedure involved 1) identifying products’ key patents as those with a patent …